RESUMO
Dasatinib is an inhibitor of BCR-ABL and SRC-family kinases for patients with imatinib-resistant or -intolerant chronic myelogenous leukemia (CML). In this international phase II trial, dasatinib was administered orally (70 mg twice daily) to patients with myeloid blast phase (MBP, n=109) or lymphoid blast phase (LBP, n=48) CML. After a minimum follow-up of 12 months (range 0.03-20.7 months), major hematologic responses were induced in 34% (MBP-CML) and 35% (LBP-CML) of patients. Major cytogenetic responses were attained in 33% (MBP-CML) and 52% (LBP-CML) of patients and complete cytogenetic responses were attained in 26 and 46%, respectively. Median progression-free survival was 6.7 (MBP-CML) and 3.0 (LBP-CML) months. Median overall survival was 11.8 (MBP-CML) and 5.3 (LBP-CML) months. Overall, dasatinib had acceptable tolerability. Fluid retention events were more frequent in the MBP-CML than the LBP-CML cohort: pleural effusion occurred in 36 and 13% (all grades) and 15 and 6% (grades 3/4), respectively. Other non-hematologic side effects were primarily grade 1/2; grade 3/4 events were recorded in Assuntos
Crise Blástica/tratamento farmacológico
, Leucemia Mielogênica Crônica BCR-ABL Positiva/tratamento farmacológico
, Leucemia Mielogênica Crônica BCR-ABL Positiva/patologia
, Inibidores de Proteínas Quinases/administração & dosagem
, Pirimidinas/administração & dosagem
, Tiazóis/administração & dosagem
, Administração Oral
, Adolescente
, Adulto
, Idoso
, Idoso de 80 Anos ou mais
, Antineoplásicos
, Benzamidas
, Terapia Combinada
, Dasatinibe
, Intervalo Livre de Doença
, Resistencia a Medicamentos Antineoplásicos
, Feminino
, Genes abl/genética
, Transplante de Células-Tronco Hematopoéticas
, Humanos
, Mesilato de Imatinib
, Leucemia Mielogênica Crônica BCR-ABL Positiva/genética
, Masculino
, Pessoa de Meia-Idade
, Piperazinas
, Inibidores de Proteínas Quinases/efeitos adversos
, Pirimidinas/efeitos adversos
, Tiazóis/efeitos adversos
, Resultado do Tratamento
, Adulto Jovem